Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.68B | $4.55B | +2.83% |
Cost of Revenue | $1.27B | $1.31B | -3.05% |
Net Income | $1.35B | $1.22B | +10.30% |
EPS (Basic) | $3.02 | $2.68 | +12.69% |
EPS (Diluted) | $3.02 | $2.67 | +13.11% |
SG&A Expense | $1.18B | $1.13B | +4.61% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.48B | $14.16B | +2.22% |
Current Assets | $5.92B | $6.2B | -4.50% |
Total Liabilities | $9.5B | $9.21B | +3.23% |
Current Liabilities | $3.37B | $1.8B | +87.31% |
Stockholders' Equity | $4.98B | $4.97B | +0.22% |
Cash & Equivalents | $1.44B | $1.57B | -8.83% |
Long-Term Debt | $5.23B | $6.56B | -20.30% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.07B | $1.1B | -2.19% |
Investing Cash Flow | $-422M | $-263M | -60.46% |
Financing Cash Flow | $-1.24B | $-1.29B | +3.57% |
Share Buybacks | $781M | $872M | -10.44% |
D&A | $242M | $253M | -4.35% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 28.8% | — | — |
ROE | 27.1% | — | — |
ROA | 9.3% | — | — |
Current Ratio | $1.76 | — | — |
Debt to Equity | $1.909 | — | — |
Other companies in Pharmaceuticals